Skip to main content
OpenTrials
Completed

NCT Number: NCT00630812

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

The purpose of this study is to examine the efficacy and safety of 26 weeks treatment with inhaled mannitol in subjects with cystic fibrosis. Previous studies have demonstrated improvements in lung function, mucociliary clearance, changes in physical properties of mucus, 24 hour sputum weight and quality of life. The results of this study are to further investigate and confirm these findings in addition to examine the effect on antibiotic use and chest infections. It is hypothesised that inhaled mannitol will have beneficial effects compared to a control treatment. An open label phase of 26 weeks duration will follow the blinded 26 week phase. During the open label phase all subjects will receive active treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cystic Fibrosis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Lung Diseases Pancreatic Diseases Respiratory Tract Diseases

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hospital Interzonal Dr Jose Penna Bahia Blanca, Bahía Blanca, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have given written informed consent to participate in this study in accordance with local regulations
  • Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value ≥ 60 mEq/L) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype)
  • Be aged > 6 years old
  • Have FEV1 >40 % and < 90% predicted
  • Be able to perform all the techniques necessary to measure lung function

Exclusion criteria

  • Investigators, site personnel directly affiliated with this study, or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted.
  • Be considered "terminally ill" or eligible for lung transplantation
  • Have had a lung transplant
  • Be using nebulized hypertonic saline in the 4 weeks prior to visit 1
  • Have had a significant episode of hemoptysis (>60 mL) in the three months prior to enrolment
  • Have had a myocardial infarction in the three months prior to enrolment
  • Have had a cerebral vascular accident in the three months prior to enrolment
  • Have had major ocular surgery in the three months prior to enrolment
  • Have had major abdominal, chest or brain surgery in the three months prior to enrolment
  • Have a known cerebral, aortic or abdominal aneurysm
  • Be breast feeding or pregnant, or plan to become pregnant while in the study
  • Be using an unreliable form of contraception (female subjects at risk of pregnancy only)
  • Be participating in another investigative drug study, parallel to, or within 4 weeks of visit 0
  • Have a known allergy to mannitol
  • Be using beta blockers
  • Have uncontrolled hypertension - systolic BP > 190 and / or diastolic BP > 100
  • Have a condition or be in a situation which in the Investigator's opinion may put the subject at significant risk, may confound results or may interfere significantly with the patient's participation in the study
  • Be 'Mannitol Tolerance Test positive'

-

Treatment and study plan

Inhaled mannitol

Drug

400 mg BD for 26 + 26 weeks

placebo comparator

Drug

BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase

Primary outcomes

  1. Change in Absolute FEV1 From Baseline Over 26 Weeks

    Time frame: 26 weeks

    Change from baseline in forced expiratory volume at one second (FEV1) averaged over 26 weeks (measured at 6,14 and 26 weeks) The mean absolute change from baseline FEV1 (mL) over 26 weeks (measured at week 6, 14 and 26) will be compared between the two treatment groups with a REML (restricted maximum likelihood) based repeated measures approach.Least square means presented are for the average change over the 6, 14, and 26 week visits.

Secondary outcomes

  1. Change in FEV1 From Baseline Over 26 Weeks - Dornase Users

    Time frame: 26 weeks

    In the subset of dornase users, the mean absolute change from baseline FEV1 (mL) averaged over 26 weeks (measured at week 6, 14 and 26) will be compared between the two treatment groups with a REML (restricted maximum likelihood) based repeated measures approach. Least square means presented are for the average change over the 6, 14, and 26 week visits.

    Change from baseline over 26 weeks (measured at 6,14, 26 weeks) in subset of dornase users

  2. Rate of Protocol Defined Pulmonary Exacerbations (PDPE)

    Time frame: 26 weeks

    Exacerbations treated with IV antibiotics and with at least 4 signs and symptoms according to Fuchs criteria (1994). Summary table presents the number with 0, 1,2 and 3 PDPEs during the 26 week treatment period.

  3. Hospitalisations Associated With Protocol Defined Pulmonary Exacerbations (PDPEs)

    Time frame: 26 weeks

    The number of hospitalisations is summarised and then the rate per person is analysed.

  4. Antibiotic Use Associated With PDPEs

    Time frame: 26 weeks

    Number of courses per person in the 26 week period is summarised and then the rate per person analysed.

  5. Absolute Change in FEV1 Percent Predicted at 26 Weeks

    Time frame: 26 weeks

    Change from baseline at 26 weeks in FEV1 percent predicted with BOCF for those with missing values at week 26

  6. Change in FVC (mL) Across 26 Weeks

    Time frame: 26 weeks

    Change from baseline in forced vital capacity (FVC) across 26 weeks (measured at 6,14 and 26 weeks)

  7. Change From Baseline FEF25-75 (mL/s) Over 26 Weeks

    Time frame: 26 weeks

    Change from baseline in forced expiratory flow at 25-75% of forced vital capacity (FEF25-75) (mL/s) averaged over 26 weeks (measured at 6,14 and 26 weeks) The mean absolute change from baseline over 26 weeks (measured at week 6, 14 and 26) was compared between the two treatment groups with a REML (restricted maximum likelihood) based repeated measures approach. Least square means presented are for the average change over the 6, 14, and 26 week visits.

  8. Sputum Weight at Baseline in Response to First Dose of Treatment

    Time frame: up to 30 mins after first dose of trial treatment

    Sputum was collected during and for 30 minutes following the administration of the first dose of study treatment.

Sponsors and collaborators

Lead sponsor

Syntara

Industry

Collaborators

  • Europe: KasaConsult bvba, Hoegaarden, Belgium
  • Resolution Latin America
  • ethica Clinical Research Inc.

Registry information

Official study title

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis- A Safety and Efficacy Study

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Mar 7, 2008
Registry last updated
Oct 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.